Phosphaden tablets (Tablets, Solution) Instructions for Use

Active Substance

Adenosine phosphate (Rec.INN registered by WHO)

Clinical-Pharmacological Group

A drug that improves tissue metabolism and energy supply

Pharmacotherapeutic Group

Metabolic agent

Pharmacological Action

Adenosine phosphate (adenosine monophosphate, AMP) is a component of the most important coenzymes that regulate redox processes in the cells and tissues of the body; it is a fragment of ATP, which carries out numerous endothermic reactions that ensure muscle activity and protein synthesis.

AMP indirectly regulates the formation of aminolevulinic acid and its conversion into protoporphyrin, and plays a role in the normalization of porphyrin synthesis.

It has a vasodilating and antiplatelet effect, improves macro- and microcirculation, which, in combination with improved tissue metabolism, determines a favorable effect on tissue trophism and regeneration processes.

There is evidence of improvement in the condition of patients with psoriasis, as well as with diabetic retinopathy.

In duodenal ulcer disease, it promotes acceleration of ulcer defect healing (does not significantly affect secretory and acid-forming functions).

Pharmacokinetics

T_1/2 – 10-30 sec. It is excreted by the kidneys in the form of metabolites.

Indications

Acute intermittent porphyria, polyneuritic syndrome (due to lead poisoning); acute thrombosis of superficial and deep veins of the extremities, acute arterial occlusion (during the stage of conservative treatment and in the postoperative period), obliterating endarteritis, venectomy (pre- and postoperative period), chronic venous insufficiency, thrombophlebitis, secondary vascular syndromes caused by spinal lesions.

Post-burn complications: non-healing wounds, trophic post-burn ulcers.

Hereditary diseases of the central nervous system (including hepatocerebral dystrophy – Konovalov-Wilson disease), multiple sclerosis; chronic hepatitis, liver cirrhosis, duodenal ulcer disease; coronary artery disease, chronic heart failure, asthenic syndrome, psoriasis, diabetic retinopathy.

ICD codes

Dosage Regimen

Administer Phosphaden primarily as part of combination therapy.

For oral administration, the single dose is 25-50 mg.

For intramuscular administration, the single dose is 20-60 mg.

Adjust the frequency of administration and treatment duration based on the specific indication and disease severity.

In acute intermittent porphyria and polyneuritic syndrome, administer intramuscularly at 40-60 mg twice daily for 10-15 days.

For vascular diseases (thrombosis, thrombophlebitis, chronic venous insufficiency), use a dose of 20-40 mg intramuscularly once or twice daily; the course typically lasts 3-4 weeks.

In chronic heart failure and coronary artery disease, administer 20-40 mg intramuscularly once daily for 2-3 weeks.

For duodenal ulcer disease, use a dose of 40-60 mg intramuscularly once daily for 15-20 days.

In chronic hepatitis and liver cirrhosis, administer 40 mg intramuscularly once daily or 50 mg orally twice daily for 3-4 weeks.

For multiple sclerosis and hereditary CNS diseases, use 40-60 mg intramuscularly once daily in repeated courses.

In ophthalmic practice for conditions like diabetic retinopathy, administer via retrobulbar injections at a dose of 20 mg daily for 10-15 days.

For psoriasis and post-burn trophic ulcers, use a dose of 40-60 mg intramuscularly once daily for 20-30 days.

Repeat treatment courses if necessary, following medical supervision.

Adverse Reactions

From the cardiovascular system dizziness, tachycardia, noise in the head.

From the digestive system nausea.

Others allergic reactions are possible.

Contraindications

Hypersensitivity to adenosine phosphate.

Use in Pregnancy and Lactation

Due to rapid metabolism, it does not have any negative effect on the fetus.

Special Precautions

Intravenous administration is allowed only in a hospital setting with monitoring of cardiac activity. Administration through central veins reduces the risk of side effects.

Adenosine phosphate is not effective for atrial fibrillation, atrial flutter, or atrial extrasystole.

Drug Interactions

Dipyridamole enhances the effect of adenosine phosphate.

Xanthine derivatives (including theophylline, caffeine) reduce the effects of ATP.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.